Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 16 de 16
Filter
Add more filters










Publication year range
1.
Zhonghua Wei Chang Wai Ke Za Zhi ; 14(7): 538-41, 2011 Jul.
Article in Chinese | MEDLINE | ID: mdl-21792768

ABSTRACT

OBJECTIVE: To investigate the relationship between methylation of the CDH1 gene promoter on the expression of E-cadherin and ß-catenin, and to evaluate the correlation with clinicopathological characteristics of the colonic carcinoma. METHODS: Methylation specific PCR (MSP) was used to detect CDH1 gene promoter methylation in the cancer tissue, adjacent tissues and normal tissues in 68 patients. The expression of E-cadherin and ß-catenin was determined by immunohistochemistry staining. RESULTS: The positive rate of CDH1 gene promoter methylation was 32.4% in adjacent tissues and 57.4% in cancer tissue, while no detectable methylation was found in all the normal tissues. The difference was statistically significant. The positive rate of E-cadherin was 92.6% in the normal tissues, 66.2% in the adjacent tissues and 44.1% in the cancer tissues. In all normal tissues, ß-catenin was expressed only at the cellular membrane but not in the cytosol or nucleus, while the expression of ß-catenin was present in the cytosol or nucleus in 29.4% of the adjacent tissues and 50.0% of the cancer tissues. The positive rate of CDH1 gene promoter methylation was negatively correlated with E-cadherin expression(r=-0.312, P=0.01) and positively correlated with ß-catenin cytosolic/nucleus expression(r=0.309, P=0.018). The differentiation and metastasis of colonic carcinoma were associated with the aberrant expression of E-cadherin, ß-catenin, and methylation of CDH1 promoter (P<0.05). CONCLUSION: CDH1 gene promoter methylation may lead to aberrant expression of E-cadherin and ß-catenin in colonic carcinoma, and may play an important role in promoting the invasion of tumor.


Subject(s)
Cadherins/genetics , Colonic Neoplasms/genetics , DNA Methylation , Promoter Regions, Genetic , beta Catenin/genetics , Adult , Aged , Aged, 80 and over , Antigens, CD , Cadherins/metabolism , Colonic Neoplasms/metabolism , Female , Humans , Male , Middle Aged , beta Catenin/metabolism
2.
J Cell Physiol ; 226(5): 1308-22, 2011 May.
Article in English | MEDLINE | ID: mdl-20945398

ABSTRACT

Recently the role of hydrogen sulphide (H(2) S) as a gasotransmitter stimulated wide interest owing to its involvement in Alzheimer's disease and ischemic stroke. Previously we demonstrated the importance of functional ionotropic glutamate receptors (GluRs) by neurons is critical for H(2) S-mediated dose- and time-dependent injury. Moreover N-methyl-D-aspartate receptor (NMDAR) antagonists abolished the consequences of H(2) S-induced neuronal death. This study focuses on deciphering the downstream effects activation of NMDAR on H(2) S-mediated neuronal injury by analyzing the time-course of global gene profiling (5, 15, and 24 h) to provide a comprehensive description of the recruitment of NMDAR-mediated signaling. Microarray analyses were performed on RNA from cultured mouse primary cortical neurons treated with 200 µM sodium hydrosulphide (NaHS) or NMDA over a time-course of 5-24 h. Data were validated via real-time PCR, western blotting, and global proteomic analysis. A substantial overlap of 1649 genes, accounting for over 80% of NMDA global gene profile present in that of H(2) S and over 50% vice versa, was observed. Within these commonly occurring genes, the percentage of transcriptional consistency at each time-point ranged from 81 to 97%. Gene families involved included those related to cell death, endoplasmic reticulum stress, calcium homeostasis, cell cycle, heat shock proteins, and chaperones. Examination of genes exclusive to H(2) S-mediated injury (43%) revealed extensive dysfunction of the ubiquitin-proteasome system. These data form a foundation for the development of screening platforms and define targets for intervention in H(2) S neuropathologies where NMDAR-activated signaling cascades played a substantial role.


Subject(s)
Cerebral Cortex/drug effects , Excitatory Amino Acid Agonists/pharmacology , Gene Expression Profiling , Neurons/drug effects , Receptors, N-Methyl-D-Aspartate/drug effects , Signal Transduction/drug effects , Sulfides/pharmacology , Animals , Blotting, Western , Cell Death , Cell Survival , Cells, Cultured , Cerebral Cortex/embryology , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Dose-Response Relationship, Drug , Gene Expression Profiling/methods , Mice , N-Methylaspartate/pharmacology , Neurons/metabolism , Neurons/pathology , Oligonucleotide Array Sequence Analysis , Proteasome Endopeptidase Complex/drug effects , Proteasome Endopeptidase Complex/genetics , Proteasome Endopeptidase Complex/metabolism , Proteomics/methods , Receptors, N-Methyl-D-Aspartate/genetics , Receptors, N-Methyl-D-Aspartate/metabolism , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , Signal Transduction/genetics , Time Factors
3.
Cell Signal ; 21(2): 237-45, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18983912

ABSTRACT

Pituitary adenylate cyclase-activating polypeptide (PACAP) is a neurotrophic peptide. Here, we show that PACAP recruits Rap1 into caveolin-enriched membrane subdomains in PC12 cells and activates Rap1, nuclear ERK1/2, Elk-1 and CREB in a caveolae-dependent manner. We reveal that GSK3beta is a novel modulator in PACAP signalling. PACAP induces phosphorylation of serine 9 in GSK3beta, which is inhibited by silencing Rap1. Lithium and valproate promote but wortmannin and LY294002 attenuate PACAP-induced phosphorylation of both GSK3beta and ERK1/2, whereas MEK inhibitor PD98059 inhibits nerve growth factor- but not PACAP-induced phosphorylation of GSK3beta, suggesting that GSK3beta operates downstream of Rapt 1 but upstream of ERK1/2 in PACAP signalling. Inhibition or stimulation of GSK3beta results in a 2-fold increase and 6-fold decrease in PACAP-induced neurite outgrowth, respectively. These results reveal an important role of caveolae in the signal transduction of PACAP and that GSK3beta is a critical regulator in PACAP-induced neuronal differentiation.


Subject(s)
Caveolae/metabolism , Glycogen Synthase Kinase 3/metabolism , Neurites/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , rap1 GTP-Binding Proteins/metabolism , Animals , Caveolae/drug effects , Caveolin 1/immunology , Glycogen Synthase Kinase 3 beta , Lithium/pharmacology , MAP Kinase Signaling System , Mitogen-Activated Protein Kinase 3/metabolism , Neurites/drug effects , PC12 Cells , Phosphorylation , RNA, Small Interfering , Rats , Signal Transduction , Time Factors , Valproic Acid/pharmacology
4.
Toxicon ; 51(6): 964-73, 2008 May.
Article in English | MEDLINE | ID: mdl-18377942

ABSTRACT

Cardiotoxin-4b (CTX-4b), isolated from Naja naja sputatrix venom, shows lethality in several cell types. Employing murine primary cortical neurons, this study was undertaken to investigate the molecular mechanisms of CTX-4b in the induction of neuronal death. CTX-4b induced a dose- and time-dependent neuronal death. Strong induction of calpains as early as 4h post-CTX-4b 75 nM treatment was detected in neurons with negligible caspase 3 activation. For the first time in cultured murine primary cortical neurons, it was noted that CTX-4b-mediated cell death triggered oxidative stress with an increase in reactive oxygen species (ROS) levels, and that application of antioxidants showed effective attenuation of cell death. Taken together, these results indicate that CTX-4b-mediated neuronal death is associated with (i) early calpain activation and (ii) oxidative stress. Most importantly, antioxidants have proved to be a promising therapeutic avenue against CTX-4b-induced neuronal death.


Subject(s)
Antioxidants/pharmacology , Calpain/pharmacology , Cell Death/drug effects , Cobra Cardiotoxin Proteins , Neurons/drug effects , Neuroprotective Agents/pharmacology , Oxidative Stress/drug effects , Animals , Cell Death/physiology , Cells, Cultured , Dose-Response Relationship, Drug , Elapid Venoms/chemistry , Electrophoresis, Polyacrylamide Gel , Mice , Neurons/pathology , Oxidative Stress/physiology , Reactive Oxygen Species/metabolism , Time Factors
5.
J Mol Microbiol Biotechnol ; 13(4): 243-7, 2007.
Article in English | MEDLINE | ID: mdl-17827975

ABSTRACT

RsAFP2 (Raphanus sativus antifungal peptide 2), an antifungal plant defensin isolated from seed of R. sativus, interacts with glucosylceramides (GlcCer) in membranes of susceptible yeast and fungi and induces membrane permeabilization and fungal cell death. However, using carboxyfluorescein-containing small unilamellar vesicles containing purified GlcCer, we could not observe permeabilization as a consequence of insertion of RsAFP2 in such vesicles. Therefore, we focused on a putative RsAFP2-induced signaling cascade downstream of RsAFP2-binding to GlcCer in fungal membranes. We show that RsAFP2 induces reactive oxygen species (ROS) in Candida albicans wild type in a dose-dependent manner, but not at all in an RsAFP2-resistant DeltagcsC. albicans mutant that lacks the RsAFP2-binding site in its membranes. These findings indicate that upstream binding of RsAFP2 to GlcCer is needed for ROS production leading to yeast cell death. Moreover, the antioxidant ascorbic acid blocks RsAFP2-induced ROS generation, as well as RsAFP2 antifungal activity. These data point to the presence of an intracellular plant defensin-induced signaling cascade, which involves ROS generation and leads to fungal cell growth arrest.


Subject(s)
Antifungal Agents/pharmacology , Candida albicans/drug effects , Defensins/pharmacology , Plant Proteins/pharmacology , Antifungal Agents/isolation & purification , Ascorbic Acid/pharmacology , Candida albicans/metabolism , Defensins/antagonists & inhibitors , Defensins/isolation & purification , Glucosylceramides/metabolism , Permeability , Plant Proteins/antagonists & inhibitors , Plant Proteins/isolation & purification , Raphanus/chemistry , Reactive Oxygen Species/antagonists & inhibitors , Reactive Oxygen Species/metabolism
6.
Neuropharmacology ; 53(5): 687-98, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17889908

ABSTRACT

Studies have shown that the lipid peroxidation by-product, 4-hydroxynonenal (HNE), is involved in many pathological events in several neurodegenerative diseases. A number of signaling pathways mediating HNE-induced cell death in the brain have been proposed. However, the exact mechanism remains unknown. In the present study, we have examined the effects of HNE on cultured primary cortical neurons and found that HNE treatment leads to cell death via apoptosis. Both the caspase and calpain proteolytic systems were activated. There were also increased levels of phospho-p53 and cell cycle-related proteins. Gene transcription was further studied using microarray analysis. Results showed that majority of the genes associated with cell cycle regulation, response to stress, and signal transduction were differentially expressed. The various categories of differentially-expressed genes suggested that there are other parallel pathways regulating HNE-induced neuronal apoptosis. Collectively, these might help to elucidate similar molecular mechanisms involved during cell death in neurodegenerative diseases.


Subject(s)
Aldehydes/pharmacology , Apoptosis/drug effects , Cerebral Cortex/cytology , Neurons/drug effects , Signal Transduction/physiology , Transcription, Genetic/physiology , Acetylcysteine/pharmacology , Animals , Calpain/metabolism , Caspases/metabolism , Cell Cycle Proteins/physiology , Cell Death/drug effects , Cell Death/physiology , Cell Survival/drug effects , Cells, Cultured , Cerebral Cortex/drug effects , Cytoskeleton/physiology , Free Radical Scavengers/pharmacology , Gene Expression Regulation/physiology , Genes, p53 , Mice , Microarray Analysis , Oxidative Stress/physiology , Signal Transduction/drug effects , Ubiquitin/physiology
7.
J Neurochem ; 103(3): 1157-67, 2007 Nov.
Article in English | MEDLINE | ID: mdl-17680996

ABSTRACT

Pituitary adenylate cyclase-activating polypeptide (PACAP), a member of the secretin/glucagon/vasoactive intestinal peptide family expressed throughout the nervous system, binds to the PACAP-specific G-protein-coupled receptor family members to promote both neuronal differentiation and survival. Although the PACAP receptor is known to activate its effector protein, adenylate cyclase (AC), and thus enhance cAMP generation, the molecular mechanism utilized by the receptor to activate AC is lacking. Here, we show that PACAP induces neurite outgrowth in PC12 cells by induction of translocation of the PACAP type 1 receptor (PAC1R) into caveolin-enriched Triton X-100-insoluble microdomains, leading to stronger PAC1R-AC interaction and elevated cAMP production. Moreover, we demonstrate that translocation of PAC1R is blocked by various treatments that selectively disrupt caveolae. As a result, intracellular cAMP level is decreased and consequently the PACAP-induced neurite outgrowth retarded. In contrast, addition of exogenous ganglioside GM1 to the cells shows the opposite effects. These results therefore identify the PACAP-induced translocation of its G-protein-coupled receptor into caveolae, where both AC and the regulating G-proteins reside, as the key molecular event in activating AC and inducing cAMP-mediated differentiation of PC12 cells.


Subject(s)
Caveolae/metabolism , Cyclic AMP/biosynthesis , Membrane Microdomains/metabolism , Neurites/metabolism , Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Adenylyl Cyclases/metabolism , Animals , Caveolae/drug effects , Cell Differentiation/drug effects , Cell Differentiation/physiology , Central Nervous System/embryology , Central Nervous System/growth & development , Central Nervous System/metabolism , Enzyme Activation/drug effects , Enzyme Activation/physiology , G(M1) Ganglioside/metabolism , G(M1) Ganglioside/pharmacology , Membrane Microdomains/drug effects , Neurites/drug effects , PC12 Cells , Protein Transport/drug effects , Protein Transport/physiology , Rats , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/drug effects , Receptors, Pituitary Adenylate Cyclase-Activating Polypeptide/metabolism , Signal Transduction/drug effects , Signal Transduction/physiology , Up-Regulation/drug effects , Up-Regulation/physiology
8.
J Control Release ; 115(2): 150-7, 2006 Oct 10.
Article in English | MEDLINE | ID: mdl-16963144

ABSTRACT

We described here a liposomal carrier system in which the targeting ligand was sulfatide, a glycosphingolipid known to bind several extracellular matrix (ECM) glycoproteins whose expression was highly up-regulated in many tumors. In vitro experiments with human glioma cell lines demonstrated that robust intracellular uptake of the liposomes depended specifically on the presence of sulfatide as the key liposomal component. Significant amount of the liposomes remained largely intact in the cytoplasm for hours following their internalization. When anticancer drug doxorubicin (DOX) was encapsulated in such liposomes, most of the drug was preferably delivered into the cell nuclei to exert its cytotoxicity. Use of this drug delivery system to deliver DOX for treatment of tumor-bearing nude mice displayed much improved therapeutic effects over the free drug or the drug carried by polyethylene glycol (PEG)-grafted liposomes. Our results demonstrate a close link between effective intracellular uptake of the drug delivery system and its therapeutic outcome. Moreover, the sulfatide-containing liposomes (SCL) may represent an interesting ligand-targeted drug carrier for a wide spectrum of cancers in which sulfatide-binding ECM glycoproteins are expressed.


Subject(s)
Antibiotics, Antineoplastic/administration & dosage , Brain Neoplasms/drug therapy , Doxorubicin/administration & dosage , Drug Delivery Systems , Glioma/drug therapy , Sulfoglycosphingolipids/pharmacology , Animals , Antibiotics, Antineoplastic/pharmacokinetics , Cell Line, Tumor , Cell Nucleus/metabolism , Cell Survival/drug effects , Cytosol/metabolism , Doxorubicin/pharmacokinetics , Drug Carriers , Humans , Liposomes , Mice , Mice, Nude , Microscopy, Fluorescence , Neoplasm Transplantation , Survival , Transplantation, Heterologous
9.
J Biol Chem ; 281(41): 30768-81, 2006 Oct 13.
Article in English | MEDLINE | ID: mdl-16895917

ABSTRACT

The segment C-terminal to the hydrophobic motif at the V5 domain of protein kinase C (PKC) is the least conserved both in length and in amino acid identity among all PKC isozymes. By generating serial truncation mutants followed by biochemical and functional analyses, we show here that the very C terminus of PKCalpha is critical in conferring the full catalytic competence to the kinase and for transducing signals in cells. Deletion of one C-terminal amino acid residue caused the loss of approximately 60% of the catalytic activity of the mutant PKCalpha, whereas deletion of 10 C-terminal amino acid residues abrogated the catalytic activity of PKCalpha in immune complex kinase assays. The PKCalpha C-terminal truncation mutants were found to lose their ability to activate mitogen-activated protein kinase, to rescue apoptosis induced by the inhibition of endogenous PKC in COS cells, and to augment melatonin-stimulated neurite outgrowth. Furthermore, molecular dynamics simulations revealed that the deletion of 1 or 10 C-terminal residues results in the deformation of the V5 domain and the ATP-binding pocket, respectively. Finally, PKCalpha immunoprecipitated using an antibody against its C terminus had only marginal catalytic activity compared with that of the PKCalpha immunoprecipitated by an antibody against its N terminus. Therefore, the very C-terminal tail of PKCalpha is a novel determinant of the catalytic activity of PKC and a promising target for selective modulation of PKCalpha function. Molecules that bind preferentially to the very C terminus of distinct PKC isozymes and suppress their catalytic activity may constitute a new class of selective inhibitors of PKC.


Subject(s)
Protein Kinase C-alpha/chemistry , Amino Acid Motifs , Amino Acid Sequence , Animals , COS Cells , Catalytic Domain , Cattle , Chlorocebus aethiops , Molecular Sequence Data , Neurons/metabolism , Protein Kinase C-alpha/metabolism , Protein Structure, Tertiary , Rats , Sequence Homology, Amino Acid , Signal Transduction
10.
J Neurochem ; 97(1): 280-91, 2006 Apr.
Article in English | MEDLINE | ID: mdl-16515545

ABSTRACT

An elevated level of cholesterol in mitochondrial membranes of Niemann-Pick disease type C1 (NPC1) mouse brains and neural cells has been found to cause mitochondrial dysfunction. In this study, we demonstrate that inhibition of intracellular cholesterol trafficking in primary neurons by class 2 amphiphiles, which mimics the major biochemical and cellular feature of NPC1, led to not only impaired mitochondrial function but also activation of the mitochondrial apoptosis pathway. In activation of this pathway both cytochrome c and Smac/Diablo were released but apoptosis-inducing factor (AIF) was not involved. Treatment of the neurons with taurine, a caspase 9-specific inhibitor, could prevent the amphiphile-induced apoptotic cell death, suggesting that formation of apoptosome, followed by caspase 9 and caspase 3 activation, might play a critical role in the neuronal death pathway. Taken together, the mitochondria-dependent death cascade induced by blocking intracellular cholesterol trafficking was caspase dependent. The findings provide clues for both understanding the molecular basis of neurodegeneration in NPC1 disease and developing therapeutic strategies for treatment of this disorder.


Subject(s)
Apoptosis/physiology , Caspases/metabolism , Cholesterol/metabolism , Mitochondrial Proteins/metabolism , Nerve Degeneration/metabolism , Signal Transduction/physiology , Animals , Apoptosis Regulatory Proteins , Carrier Proteins/metabolism , Caspase 3 , Caspase 9 , Caspase Inhibitors , Cells, Cultured , Cerebral Cortex/metabolism , Cerebral Cortex/pathology , Cerebral Cortex/physiopathology , Cytochromes c/metabolism , Enzyme Activation/drug effects , Enzyme Activation/physiology , Mice , Mitochondria/drug effects , Mitochondria/metabolism , Nerve Degeneration/physiopathology , Neurons/drug effects , Neurons/metabolism , Neurons/pathology , Niemann-Pick Diseases/metabolism , Niemann-Pick Diseases/physiopathology , Protein Transport/drug effects , Protein Transport/physiology , Signal Transduction/drug effects , Surface-Active Agents/pharmacology
11.
Cell Signal ; 18(9): 1473-81, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16427251

ABSTRACT

PRK1 is a lipid- and Rho GTPase-activated serine/threonine protein kinase implicated in the regulation of receptor trafficking, cytoskeletal dynamics and tumorigenesis. Although Rho binding has been mapped to the HR1 region in the regulatory domain of PRK1, the mechanism involved in the control of PRK1 activation following Rho binding is poorly understood. We now provide the first evidence that the very C-terminus beyond the hydrophobic motif in PRK1 is essential for the activation of this kinase by RhoA. Deletion of the HR1 region did not completely abolish the binding of PRK1-DeltaHR1 to GTPgammaS-RhoA nor the activation of this mutant by GTPgammaS-RhoA in vitro. In contrast, removing of the last six amino acid residues from the C-terminus of PRK1 or truncating of a single C-terminal residue from PRK1-DeltaHR1 completely abrogated the activation of these mutants by RhoA both in vitro and in vivo. The critical dependence of the very C-terminus of PRK1 on the signaling downstream of RhoA was further demonstrated by the failure of the PRK1 mutant lacking its six C-terminal residues to augment lisophosphatidic acid-elicited neurite retraction in neuronal cells. Thus, we show that the HR1 region is necessary but not sufficient in eliciting a full activation of PRK1 upon binding of RhoA. Instead, such activation is controlled by the very C-terminus of PRK1. Our results also suggest that the very C-terminus of PRK1, which is the least conserved among members of the protein kinase C superfamily, is a potential drug target for pharmacological intervention of RhoA-mediated signaling pathways.


Subject(s)
Protein Kinase C/metabolism , Signal Transduction/physiology , rhoA GTP-Binding Protein/metabolism , Animals , Cell Line , Enzyme Activation , Guanosine 5'-O-(3-Thiotriphosphate)/metabolism , Humans , Lysophospholipids/metabolism , Mice , Muscle Contraction/physiology , Mutation , Protein Kinase C/chemistry , Protein Kinase C/genetics , Protein Structure, Tertiary , Rats , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , rhoA GTP-Binding Protein/genetics
12.
FASEB J ; 18(14): 1722-4, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15375078

ABSTRACT

Mammalian serine/threonine protein kinases, except for TGF-beta receptor kinase family, are intracellular proteins. PRK1/PKN is a member of the protein kinase C superfamily of serine/threonine kinases and is one of the first identified effectors for RhoA GTPase. However, the role of PRK1 in mediating signaling downstream of activated RhoA is largely unknown. Here, we present evidence that identifies a novel plasma membrane pool of PRK1. This integral membrane form of PRK1 is catalytically active. The phosphorylation of serine377 of PRK1 is required for its integration into membranes. This integration is essential for PRK1 to function as a Rho effector as only the integral plasma membrane PRK1 is able to initiate RhoA-mediated and ligand-dependent transcriptional activation of the androgen receptor in human epithelial cells and to mediate RhoA-induced neurite retraction in mouse neuronal cells. These results indicate that RhoA signals via the integral membrane pool of its effectors in its immediate vicinity at the plasma membrane, thus establishing a new paradigm in mammalian cell signaling.


Subject(s)
Cell Membrane/enzymology , Protein Kinase C/metabolism , Signal Transduction , rhoA GTP-Binding Protein/metabolism , Amino Acid Substitution , Animals , Cell Line , Cricetinae , Humans , Lysophospholipids/pharmacology , Mice , Neurons/enzymology , Protein Kinase C/genetics , Rats , Receptors, Androgen/metabolism
13.
Biomaterials ; 25(21): 5181-9, 2004 Sep.
Article in English | MEDLINE | ID: mdl-15109842

ABSTRACT

In the present work, we developed a novel drug delivery system, liposomes-in-microsphere (LIM) of biodegradable polymers, which is conceived from a combination of the polymer- and the lipid-based delivery systems and can thus integrate the advantages and avoid the drawbacks of the two systems. Liposomes were encapsulated into microspheres of biodegradable polymers by the solvent extraction/evaporation process to form LIMs. The integrity of the liposomes was preserved by modifying the microencapsulation process and coating the liposomes with chitosan. We demonstrated by scanning electron microscopy, laser light scattering and fluorescence spectroscopy that the particle size and surface morphology of the polymeric microspheres did not change significantly with the liposomes encapsulated, the liposomes remained intact within the polymeric matrix of the microspheres, and the encapsulated liposomes could be released from the microspheres in a controlled manner at a nearly constant release rate after an initial off-release period. Decreasing the particle size of liposomes and increasing the pore size of the polymeric matrix shortened the initial off-release period and increased the liposome release rate. In conclusion, a novel drug delivery system, liposomes-in-microsphere, was successfully developed and characterized. The liposome release kinetics could be controlled by the composition and fabrication parameters of the liposomes and polymeric microspheres. Such a novel controlled release system may have potential to be applied for drug delivery and gene therapy.


Subject(s)
Coated Materials, Biocompatible/chemistry , Contraceptive Agents/chemistry , Liposomes/chemistry , Polymers/chemistry , Diffusion , Materials Testing , Microspheres , Particle Size , Phospholipids/chemistry , Surface Properties
14.
Biochem Biophys Res Commun ; 315(2): 408-17, 2004 Mar 05.
Article in English | MEDLINE | ID: mdl-14766223

ABSTRACT

Niemann-Pick disease type C (NPC) is a juvenile neurodegenerative disorder characterized by premature neuronal loss and altered cholesterol metabolism. Previous reports applying an 8-h exposure of U18666A, a cholesterol transport-inhibiting agent, demonstrated a dose-dependent reduction in beta-amyloid (Abeta) deposition and secretion in cortical neurons, with no significant cell injury. In the current study, we examined the chronic effect of 24-72h of U18666A treatment on primary cortical neurons and several cell lines. Our results showed caspase-3 activation and cellular injury in U18666A-treated cortical neurons but not in the cell lines, suggesting cell death by apoptosis only occurred in cortical neurons after chronic exposure to U18666A. We also demonstrated through filipin staining the accumulation of intracellular cholesterol in cortical neurons treated with U18666A, indicating the phenotypic mimic of NPC by U18666A. However, additions of 10 and 25microM pravastatin with 0.5microg/ml U18666A significantly attenuated toxicity. Taken together, these data showed for the first time that U18666A induces cell death by apoptosis and suggested an important in vitro model system to study NPC.


Subject(s)
Androstenes/pharmacology , Apoptosis , Cerebral Cortex/drug effects , Enzyme Inhibitors/pharmacology , Neurons/drug effects , Animals , Anticholesteremic Agents/pharmacology , Blotting, Western , CHO Cells , Caspase 3 , Caspases/metabolism , Cell Line , Cell Survival , Cells, Cultured , Cholesterol/metabolism , Cricetinae , Dose-Response Relationship, Drug , Enzyme Activation , Filipin/metabolism , Humans , Mice , Microscopy, Electron , NIH 3T3 Cells , Neurons/metabolism , Pravastatin/pharmacology , Time Factors
15.
Chem Pharm Bull (Tokyo) ; 51(3): 241-6, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12612404

ABSTRACT

The effects of antimalarial drugs halofantrine and lumefantrine on the fluoresence anisotropy of diphenylhexatriene (DPH)-containing phospholipid vesicles have been examined. Lumefantrine increases DPH anisotropy, indicating a condensing effect on bilayers of dipalmitoylphosphatidyl choline (DPPC), dioleoylphosphatidylcholine (DOPC), egg lecithin and mouse erythrocyte membranes (including membranes isolated from plasmodial-infected mice). Its condensing effect is more pronounced in bilayers of lower microviscosity. In contrast, increases or decreases in DPH anisotropy are observed with halofantrine, depending on the nature of the lipid. Decreases in anisotropy, which reflect a perturbing effect, are observed in bilayers of high microviscosity (for example, gel state of DPPC bilayers). Increases in anisotropy are observed in bilayers of low microviscosity (such as DOPC and egg lecithin bilayers). The perturbing effect of halofantrine is further confirmed by the increases in permeability of calcein-containing DPPC vesicles in the presence of the drug. However the perturbative effects of halofantrine are observed to the same magnitude in uninfected and plasmodial-infected erythrocyte membranes, and may not be relevant to the antimalarial action of the drug. In contrast, the condensing effect of lumefantrine is significantly greater in infected erythrocyte membranes and may contribute to its antimalarial action.


Subject(s)
Antimalarials/metabolism , Ethanolamines/metabolism , Fluorenes/metabolism , Lipid Bilayers/metabolism , Phenanthrenes/metabolism , 1,2-Dipalmitoylphosphatidylcholine/metabolism , Animals , Antimalarials/chemistry , Erythrocyte Membrane/metabolism , Ethanolamines/chemistry , Fluorenes/chemistry , Lumefantrine , Male , Mice , Phenanthrenes/chemistry , Phosphatidylcholines/metabolism
16.
J Control Release ; 84(3): 151-60, 2002 Dec 05.
Article in English | MEDLINE | ID: mdl-12468218

ABSTRACT

Human serum albumin (HSA) was encapsulated as a model protein in microspheres of biodegradable and biocompatible polymers by the water-in-oil-in-water (w/o/w) emulsion solvent extraction/evaporation (double emulsion) technique for purpose of controlled release. To improve the properties and control the rate of drug release of the delivery vehicle, materials with different hydrophobicity from that of their conventional counterparts, such as poly(lactide-co-ethylene glycol) (PELA) in place of poly(lactide-co-glycolide) (PLGA) as the polymer matrix, ethyl acetate/acetone in place of dichloride methane (DCM) as the (co)solvent and d-alpha tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS) as the additive, were used to prepare the microspheres. It has been found that PELA microspheres, compared with PLGA ones, were slightly smaller in size if prepared at identical emulsification strength. They had more porous surface and internal structure, higher encapsulation efficiency (EE) and more rapid in vitro release rate. Furthermore, the physical properties of the microspheres were also affected by the presence of solvents and additives and their properties. Our results suggest that these materials could have interesting potential applications in preparation of polymeric microspheres for controlled protein release.


Subject(s)
Lactates/chemistry , Lactic Acid/chemistry , Materials Testing , Polyethylene Glycols/chemistry , Polyglycolic Acid/chemistry , Polymers/chemistry , Delayed-Action Preparations/chemistry , Drug Carriers/chemistry , Drug Compounding/methods , Emulsions , Humans , Hydrophobic and Hydrophilic Interactions , Kinetics , Microspheres , Particle Size , Polylactic Acid-Polyglycolic Acid Copolymer , Serum Albumin/chemistry , Surface Properties
SELECTION OF CITATIONS
SEARCH DETAIL
...